

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No. IVD 994

RECEIPT #6
PGT

In re patent application of: ABRAMOVICI et al.

Serial No.: 09/446,601

Filed: 22 December 1999

Group Art Unit: 1614

Preliminary Class: 514

For: SOLID PHARMACEUTICAL COMPOSITION
CONTAINING BENZOFURAN DERIVATIVES



CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being deposited on the date indicated below with the United States Postal Service as first class mail addressed to: Commissioner for Patents, Office of Initial Patent Examination's Customer Service Center, Washington, DC 20231

Paul E. Dupont
Name

May 20, 2000
Date

Commissioner for Patents
Office of Initial Patent Examination's
Customer Service Center
Washington, DC 20231

Dear Sir:

REQUEST FOR CORRECTED FILING RECEIPT

Attention is called to an error which was discovered in the Filing Receipt for the above-identified application. A copy of the Filing Receipt showing the following correction is enclosed herewith.

The following addresses should read as follows:

Jean-Claude Gautier, Clapiers, France.

In view of the foregoing, applicants respectfully request issuance of a corrected filing receipt for the above-identified application.

Date:

May 20, 2000

Respectfully submitted,

Paul E. Dupont
Paul E. Dupont
Reg. No. 27,438

Address:
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355
Tele: (610) 889-6338
Facsimile: (610) 889-8799

FILING RECEIPT



OC00000005119498

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark OfficeAddress: ASSISTANT SECRETARY AND
COMMISSIONER OF PATENT AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/446,601	04/03/2000	1614	1006	IVD994	2	13	1

SANOFI SYNTHELABO INC
9 GREAT VALLEY PARKWAY
PO BOX 3026
MALVERN, PA 19355

REC'D MAY 18 2000


Date Mailed: 05/16/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

BERNARD ABRAMOVICI, JUVIGNAC, FRANCE;
 JEAN-CLAUDE GAUTIER, CIAPIERS, FRANCE;
 JEAN-CLAUDE GROMENIL, MONTBAZIN, FRANCE;
 JEAN-MARIE MARRIER, LATTES, FRANCE;

Clapiers, France



Continuing Data as Claimed by Applicant

THIS APPLICATION IS A 371 OF PCT/FR98/01285 06/19/1998

Foreign Applications

FRANCE 97/07795 06/23/1997

If Required, Foreign Filing License Granted 05/16/2000

Title

SOLID PHARMACEUTICAL COMPOSITION CONTAINING BENZOFURANE DERIVATIVES

Preliminary Class

514

Data entry by : ORDENEZ, MARTIN

Date: 05/16/2000



LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
 Office of Initial Patent Examination
 Customer Service Center
 Washington, DC 20231

RECEIVED
 JUN 27 2000
 TELECOMMUNICATIONS